Cyclacel Pharmaceuticals, Inc.
CYCC
$0.23
-$0.0152-6.20%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 45.63% | 26.34% | 13.96% | -6.40% | -32.51% |
| Total Depreciation and Amortization | -58.06% | -38.71% | -19.35% | -3.13% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.46% | -32.03% | -21.85% | -9.18% | 2.96% |
| Change in Net Operating Assets | -63.77% | 159.88% | 2,113.71% | 514.91% | 290.64% |
| Cash from Operations | 39.30% | 43.29% | 53.45% | 22.64% | 14.03% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | 14.29% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 100.00% | 14.29% | 33.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,790.22% | 333.63% | -67.21% | -67.21% | -97.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 75.12% | 50.25% | 24.88% | 0.00% | 0.00% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,712.84% | 386.01% | -72.68% | -71.71% | -102.84% |
| Foreign Exchange rate Adjustments | 235.51% | 346.75% | 199.29% | 180.16% | -97.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.32% | 77.98% | 52.55% | 17.83% | -7.56% |
